Skip to main content
Pixium Vision logo

Pixium Vision — Investor Relations & Filings

Ticker · ALPIX ISIN · FR001400JX97 LEI · 96950046OPLRLKKEOO08 PA Manufacturing
Open in API
Filings indexed 440 across all filing types
Latest filing 2020-01-13 Regulatory Filings
Country FR France
Listing PA ALPIX

About Pixium Vision

https://www.pixium-vision.com/

Pixium Vision was a bioelectronics company that developed bionic vision systems to restore partial sight for patients with retinal diseases. Its core technology, the PRIMA System, is a photovoltaic subretinal implant designed to treat vision loss from advanced atrophic dry age-related macular degeneration (dry AMD). The system uses specialized glasses to project near-infrared light onto the implant, which converts the light into electrical signals to stimulate retinal cells and create a form of prosthetic vision. The company's assets, including the PRIMA technology and its ongoing European pivotal trial (PRIMAvera), were acquired by Science Corporation in late 2023. The trials and device manufacturing are now sponsored by La Science SAS.

Recent filings

Filing Released Lang Actions
Pixium Vision annonce l’implantation réussie de son système Prima chez un premier patient aux Etats-Unis
Regulatory Filings Classification · 100% confidence The document is a press release dated January 13, 2020, announcing a significant operational milestone: the successful implantation of the Prima system in a first patient in the United States for dry Age-related Macular Degeneration (AMD). It contains quotes from the CEO and the operating physician, details about the ongoing clinical trial feasibility study, and contact information for investors and media. This format—a formal announcement of a key event, often related to clinical progress or business updates, released to the public and investors—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change announcement (MANG), and it serves as an immediate update on business progress, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's purely operational news. Given the context of clinical trial progress and future filing expectations ('Cette étude, nécessaire à l'obtention des autorisations de commercialisation, devrait être déposée au S1 2020'), it functions as a material, non-periodic disclosure. However, since it is a formal announcement of a major event rather than a standardized financial summary, and it doesn't fit the specific definitions of DIV, CAP, or MANG, the most appropriate general category for material, non-standardized corporate news is RNS (Regulatory Filings/General Announcement). If the company regularly issues press releases for clinical updates, RNS is the standard classification for such material news that isn't a formal financial report.
2020-01-13 French
Pixium Vision announces successful implantation of first patient in the US with the Prima System
Regulatory Filings Classification · 100% confidence The document is a press release dated January 13, 2020, announcing a significant operational milestone: the successful implantation of the first patient in the US with the Prima System for dry-AMD. It contains quotes from the CEO and medical staff, details about the clinical trial progress, and contact information. This format is characteristic of an initial announcement of key business or clinical developments, rather than a comprehensive periodic financial report (like 10-K or IR), a formal regulatory filing (like DEF 14A or DVA), or a transcript. It is best classified as an Earnings Release (ER) if it were tied to financial results, but since it is a specific operational/clinical update, it fits best under the general category for initial announcements or news releases that aren't strictly financial results or regulatory filings. Given the options, 'ER' (Earnings Release) is often used broadly for initial results announcements, but 'RNS' (Regulatory Filings/General Announcements) is a strong fallback for significant, non-standard announcements. However, since this is a major operational update announcing a clinical milestone, and it is not a formal financial report, it most closely resembles an announcement of results or progress. Since it is not explicitly an earnings report, and it is a formal announcement, 'RNS' is the most appropriate general category for significant, non-standard corporate news releases that don't fit other specific categories like M&A (TAR) or Capital Change (CAP). Given the context of a clinical trial milestone announcement, it is a significant corporate event announcement.
2020-01-13 English
Pixium Vision to Participate in Digital Medicine & Medtech Showcase Conference in San Francisco and Meet Investors
Regulatory Filings Classification · 100% confidence The document is a press release dated January 9, 2020, announcing that Pixium Vision will participate in a conference ('Digital Medicine & Medtech Showcase') and meet with investors during that time. It details the CEO's presentation schedule and mentions investor meetings. This type of announcement, which communicates future corporate activities aimed at investors (like conference participation and meetings), is best classified as an Investor Presentation (IP) if it were the presentation itself, or more generally, a communication about investor relations activities. Since it is an announcement about attending a conference where presentations will be given, and it is not a formal regulatory filing (like 10-K, ER, or IR), it falls under general investor communication. However, none of the codes perfectly match a 'Conference Participation Announcement'. Given the options, this is a communication intended for investors about upcoming engagement. It is not a formal Earnings Release (ER), Interim Report (IR), or a specific transaction report (DIV, SHA, POS). It is closest to an Investor Presentation (IP) in spirit, but it is an announcement *about* attending an event, not the presentation material itself. Following the 'MENU VS MEAL' rule, if this were a short announcement about a report, it would be RPA/RNS. Since this is an announcement of future corporate activity targeting investors, and it is not a standard regulatory filing, it is most appropriately categorized as a general Regulatory Filing (RNS) as a fallback for non-standard investor news, or potentially IP if we interpret it as preparatory investor material. Given the content is purely about conference attendance and investor meetings, and it's a short press release, RNS (Regulatory Filings - general regulatory announcements and fallback) is the safest classification, as it is not a formal report itself.
2020-01-09 English
Pixium Vision participera au Digital Medecine & Medtech Showcase à San Francisco et rencontrera des investisseurs
Regulatory Filings Classification · 100% confidence The document is a press release dated January 9, 2019, announcing that Pixium Vision will participate in the Digital Medecine & Medtech Showcase in San Francisco and will meet with investors during the J.P. Morgan Healthcare Conference. The content focuses on scheduling, presentation topics (strategy and clinical updates), and contact information. This is a typical announcement regarding future investor engagement and corporate events, not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed presentation (IP). Since it is an announcement about corporate activities aimed at investors and the market, it best fits the general category for investor-related news that isn't a specific financial report or management change. Given the options, this type of forward-looking corporate communication, often released via regulatory channels but focused on investor relations activities, is most closely aligned with a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the actual presentation slides. However, since it is an announcement *about* attending a conference and meeting investors, and not the presentation itself, RNS serves as the most appropriate general regulatory announcement category for non-standard disclosures, or it could be considered a form of Investor Relations communication. Given the context of investor meetings and conference participation announcements, RNS (Regulatory Filings/General Announcement) is the safest classification when a more specific 'Investor Event Announcement' code is unavailable. It is definitely not a formal report (10-K, IR, ER).
2020-01-09 French
Bilan du second semestre du contrat de liquidité contracté avec la société de bourse Gilbert Dupont
Transaction in Own Shares Classification · 98% confidence The document is titled "Bilan du second semestre du contrat de liquidité contracté avec la société de bourse Gilbert Dupont" (Balance sheet of the second half of the liquidity contract concluded with the stock brokerage firm Gilbert Dupont) and provides detailed transaction data (purchases and sales of shares, cash balances) related to a liquidity agreement for the period ending December 31, 2019. It includes annexes detailing activity for S2 2019 and S1 2019. This type of regular reporting on share repurchase/trading activity under a specific agreement strongly aligns with the definition of 'Transaction in Own Shares' (POS), which covers share repurchase programs or similar activities involving the company's own stock.
2020-01-03 English
H2 2019 update on Pixium Vision’s liquidity agreement with Gilbert Dupont
Transaction in Own Shares Classification · 95% confidence The document is titled "H2 2019 update on Pixium Vision's liquidity agreement with Gilbert Dupont" and provides specific figures regarding the cash position and number of shares held in a liquidity account as of December 31, 2019, along with transaction details for H2 2019 and H1 2019. This type of disclosure relates to the management of the company's own shares or capital structure, specifically concerning a liquidity agreement (market making/stabilization). This aligns best with the 'Transaction in Own Shares' (POS) category, which covers share repurchase/issuance activities, or potentially 'Capital/Financing Update' (CAP). However, since it details the activity of shares held under a specific agreement for market liquidity, POS is the most precise fit among the options provided, as it directly concerns the company's own shares being managed in the market. It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS).
2020-01-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.